Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Guest Dr. Glenwood Goss discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Journal of Clinical Oncology (JCO) Podcast
JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
Infections in Two Diet Strategies in HSCT and Leukemia Patients
JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time?
The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC
Get summaries like this every morning.
Free AI-powered recaps of Journal of Clinical Oncology (JCO) Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.